Polymorphisms for predicting disease and treatment outcome
CA 2494262 A1 · Owner: Lenz, Heinz-Josef · Inventors: Stoehlmacher, Jan; Lenz, Heinz-Josef; Park, David (Jong-Han)
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 31, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 31, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 31, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.